Corient Private Wealth LLC Purchases 11,907 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Corient Private Wealth LLC increased its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 20.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,073 shares of the company’s stock after purchasing an additional 11,907 shares during the quarter. Corient Private Wealth LLC’s holdings in GE HealthCare Technologies were worth $5,341,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GEHC. Private Advisor Group LLC lifted its position in GE HealthCare Technologies by 20.0% during the third quarter. Private Advisor Group LLC now owns 23,596 shares of the company’s stock worth $1,605,000 after purchasing an additional 3,925 shares during the period. NBC Securities Inc. acquired a new position in GE HealthCare Technologies during the third quarter worth about $80,000. Victory Capital Management Inc. raised its stake in GE HealthCare Technologies by 7.1% during the third quarter. Victory Capital Management Inc. now owns 686,418 shares of the company’s stock worth $46,704,000 after acquiring an additional 45,227 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in GE HealthCare Technologies by 9.2% during the third quarter. Assenagon Asset Management S.A. now owns 7,051 shares of the company’s stock worth $480,000 after acquiring an additional 594 shares in the last quarter. Finally, Versor Investments LP raised its stake in GE HealthCare Technologies by 10.6% during the third quarter. Versor Investments LP now owns 6,600 shares of the company’s stock worth $449,000 after acquiring an additional 630 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Table of Contents

Insiders Place Their Bets

In other GE HealthCare Technologies news, CEO Jan Makela sold 66,955 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the transaction, the chief executive officer now directly owns 63,348 shares in the company, valued at approximately $5,165,395.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Jan Makela sold 66,955 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total value of $5,459,510.70. Following the transaction, the chief executive officer now directly owns 63,348 shares in the company, valued at approximately $5,165,395.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Frank R. Jimenez bought 1,315 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was purchased at an average price of $76.52 per share, for a total transaction of $100,623.80. Following the completion of the acquisition, the insider now owns 75,796 shares in the company, valued at $5,799,909.92. The disclosure for this purchase can be found here. Company insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Stock Performance

NASDAQ:GEHC opened at $79.85 on Tuesday. The company has a market capitalization of $36.45 billion, a PE ratio of 23.35, a P/E/G ratio of 2.87 and a beta of 1.26. The company has a 50 day simple moving average of $84.90 and a two-hundred day simple moving average of $80.69. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06. GE HealthCare Technologies Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.90 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.90. The firm had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.80 billion. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.85 EPS. Research analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th were issued a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.15%. The ex-dividend date of this dividend was Thursday, April 18th. GE HealthCare Technologies’s payout ratio is 3.51%.

Analyst Ratings Changes

Several brokerages have commented on GEHC. Argus boosted their target price on GE HealthCare Technologies from $80.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Bank of America lowered their target price on GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Citigroup upped their price objective on GE HealthCare Technologies from $88.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Morgan Stanley upped their price objective on GE HealthCare Technologies from $74.00 to $86.00 and gave the company an “equal weight” rating in a research note on Monday, February 12th. Finally, HSBC initiated coverage on GE HealthCare Technologies in a research note on Thursday, February 15th. They issued a “buy” rating and a $100.00 price objective for the company. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.80.

Read Our Latest Report on GE HealthCare Technologies

GE HealthCare Technologies Profile

(Free Report)

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.